Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

Érika Cosset, Sten Ilmjärv, Valérie Dutoit, Kathryn Elliott, Tami von Schalscha, Maria F. Camargo, Alexander Reiss, Toshiro Moroishi, Laetitia Seguin, German Gomez, Jung Soon Moo, Olivier Preynat-Seauve, Karl Heinz Krause, Hervé Chneiweiss, Jann N Sarkaria, Kun Liang Guan, Pierre Yves Dietrich, Sara M. Weis, Paul S. Mischel, David A. Cheresh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the “proneural” and “classical” subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors. Cosset et al. identify a subset of glioblastoma within the proneural and the classical subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression, and are sensitive to agents disrupting the pathway such as cilengitide.

Original languageEnglish (US)
Pages (from-to)856-868.e5
JournalCancer Cell
Volume32
Issue number6
DOIs
StatePublished - Dec 11 2017

Fingerprint

Glioblastoma
Integrins
Facilitative Glucose Transport Proteins
Neoplastic Stem Cells
Transcriptome
Neoplasms
Stem Cells
Phenotype
Neurons
Mutation
Cilengitide
Therapeutics

Keywords

  • cancer stem cells
  • glioblastoma
  • glucose metabolism
  • Glut3
  • integrin

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Cosset, É., Ilmjärv, S., Dutoit, V., Elliott, K., von Schalscha, T., Camargo, M. F., ... Cheresh, D. A. (2017). Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell, 32(6), 856-868.e5. https://doi.org/10.1016/j.ccell.2017.10.016

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. / Cosset, Érika; Ilmjärv, Sten; Dutoit, Valérie; Elliott, Kathryn; von Schalscha, Tami; Camargo, Maria F.; Reiss, Alexander; Moroishi, Toshiro; Seguin, Laetitia; Gomez, German; Moo, Jung Soon; Preynat-Seauve, Olivier; Krause, Karl Heinz; Chneiweiss, Hervé; Sarkaria, Jann N; Guan, Kun Liang; Dietrich, Pierre Yves; Weis, Sara M.; Mischel, Paul S.; Cheresh, David A.

In: Cancer Cell, Vol. 32, No. 6, 11.12.2017, p. 856-868.e5.

Research output: Contribution to journalArticle

Cosset, É, Ilmjärv, S, Dutoit, V, Elliott, K, von Schalscha, T, Camargo, MF, Reiss, A, Moroishi, T, Seguin, L, Gomez, G, Moo, JS, Preynat-Seauve, O, Krause, KH, Chneiweiss, H, Sarkaria, JN, Guan, KL, Dietrich, PY, Weis, SM, Mischel, PS & Cheresh, DA 2017, 'Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma', Cancer Cell, vol. 32, no. 6, pp. 856-868.e5. https://doi.org/10.1016/j.ccell.2017.10.016
Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF et al. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):856-868.e5. https://doi.org/10.1016/j.ccell.2017.10.016
Cosset, Érika ; Ilmjärv, Sten ; Dutoit, Valérie ; Elliott, Kathryn ; von Schalscha, Tami ; Camargo, Maria F. ; Reiss, Alexander ; Moroishi, Toshiro ; Seguin, Laetitia ; Gomez, German ; Moo, Jung Soon ; Preynat-Seauve, Olivier ; Krause, Karl Heinz ; Chneiweiss, Hervé ; Sarkaria, Jann N ; Guan, Kun Liang ; Dietrich, Pierre Yves ; Weis, Sara M. ; Mischel, Paul S. ; Cheresh, David A. / Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. In: Cancer Cell. 2017 ; Vol. 32, No. 6. pp. 856-868.e5.
@article{d18878212ded4990a3ca92128d2e4061,
title = "Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma",
abstract = "While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the “proneural” and “classical” subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors. Cosset et al. identify a subset of glioblastoma within the proneural and the classical subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression, and are sensitive to agents disrupting the pathway such as cilengitide.",
keywords = "cancer stem cells, glioblastoma, glucose metabolism, Glut3, integrin",
author = "{\'E}rika Cosset and Sten Ilmj{\"a}rv and Val{\'e}rie Dutoit and Kathryn Elliott and {von Schalscha}, Tami and Camargo, {Maria F.} and Alexander Reiss and Toshiro Moroishi and Laetitia Seguin and German Gomez and Moo, {Jung Soon} and Olivier Preynat-Seauve and Krause, {Karl Heinz} and Herv{\'e} Chneiweiss and Sarkaria, {Jann N} and Guan, {Kun Liang} and Dietrich, {Pierre Yves} and Weis, {Sara M.} and Mischel, {Paul S.} and Cheresh, {David A.}",
year = "2017",
month = "12",
day = "11",
doi = "10.1016/j.ccell.2017.10.016",
language = "English (US)",
volume = "32",
pages = "856--868.e5",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

AU - Cosset, Érika

AU - Ilmjärv, Sten

AU - Dutoit, Valérie

AU - Elliott, Kathryn

AU - von Schalscha, Tami

AU - Camargo, Maria F.

AU - Reiss, Alexander

AU - Moroishi, Toshiro

AU - Seguin, Laetitia

AU - Gomez, German

AU - Moo, Jung Soon

AU - Preynat-Seauve, Olivier

AU - Krause, Karl Heinz

AU - Chneiweiss, Hervé

AU - Sarkaria, Jann N

AU - Guan, Kun Liang

AU - Dietrich, Pierre Yves

AU - Weis, Sara M.

AU - Mischel, Paul S.

AU - Cheresh, David A.

PY - 2017/12/11

Y1 - 2017/12/11

N2 - While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the “proneural” and “classical” subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors. Cosset et al. identify a subset of glioblastoma within the proneural and the classical subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression, and are sensitive to agents disrupting the pathway such as cilengitide.

AB - While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the “proneural” and “classical” subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors. Cosset et al. identify a subset of glioblastoma within the proneural and the classical subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression, and are sensitive to agents disrupting the pathway such as cilengitide.

KW - cancer stem cells

KW - glioblastoma

KW - glucose metabolism

KW - Glut3

KW - integrin

UR - http://www.scopus.com/inward/record.url?scp=85035760976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035760976&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2017.10.016

DO - 10.1016/j.ccell.2017.10.016

M3 - Article

VL - 32

SP - 856-868.e5

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -